Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-951 Open-Label Extension in Advanced Parkinson's Disease
NCT04750226Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2021
- Primary completion
- Apr 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of foscarbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc.. Started Feb 2021; status: completed.
02
Drugs
foscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04750226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750226.